論文・技術情報追加のお知らせ

①A nationwide pharmacovigilance investigation on trends and seriousness of adverse events induced by anti-obesity medication.

抗肥満薬による重篤な有害事象リスク調査研究

対象DB：KAERS

②Clopidogrel as a Distinctive Cause of Insulin Autoimmune Syndrome: A Systematic Case Review.

クロピドグレル誘発性IASのリスク調査研究

対象DB：FAERS

③Safety profiles of methylphenidate, amphetamine, and atomoxetine: analysis of spontaneous reports submitted to the food and drug administration adverse event reporting system.

ADHD治療薬メチルフェニデート、アンフェタミン、アトモキセチンの安全性評価研究

対象DB：FAERS

④Bleeding Complications in Vancomycin-Induced Thrombocytopenia: A Real-World Postmarketing Pharmacovigilance Analysis.

血小板減少症患者における、バンコマイシンと出血性合併症の関連性評価研究

対象DB：FAERS

⑤Signal detection of adverse events associated with gabapentinoid use for chronic pain.

慢性疼痛患者における、ガバペンチノイドによる有害事象調査研究

対象DB：FAERS

⑥Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL.

慢性リンパ性白血病患者における、イブルチニブとオビヌツズマブの心血管系有害事象評価研究

対象DB：EudraVigilance

⑦P-Glycoprotein Mediated Interaction is A Risk Factor For Qt Prolongation in Concomitant Use of Antipsychotics and Ssris As P-Glycoprotein Mediated Inhibitors: Analysis of The Japanese Adverse Drug Event Report Database.

hERG阻害作用を持つ抗精神病薬による、QT延長リスク調査研究

対象DB：JADER